Validation of prognostic indices using the frailty model

Lifetime Data Analysis

Volumn 15, Issue 1, 2009, Pages 59-78

  Legrand, C ^a,b   Duchateau, L ^c   Janssen, P ^d   Ducrocq, V ^e   Sylvester, R ^a  

^a EORTC DATA CENTER   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

^e CEMAGREF   (France)

Author keywords

Bladder cancer; Frailty model; Multicenter clinical trial; Prognostic index; Validation

Indexed keywords

ANALYSIS OF VARIANCE; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; FACTUAL DATABASE; HUMAN; MORTALITY; MULTICENTER STUDY; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SAMPLE SIZE; SURVIVAL;

ANALYSIS OF VARIANCE; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; HUMANS; MULTICENTER STUDIES AS TOPIC; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 58649120278     PISSN: 13807870     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10985-008-9092-2     Document Type: Article

References (44)

1. P Allard P Bernard Y Fradet B Tetu 1998 The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index Brit J Urol 81 692 698
2. DG Altman P Royston 2000 What do we mean by validating a prognostic model? Stat Med 19 453 473
3. RW Blamey IO Ellis SE Pinder AH Lee RD Macmillan 2007 Survival of invasive breast cancer according to the Nottingham Prognostic Index in case diagnosed in 1990-1999 Eur J Cancer 43 1548 1555
4. F Blanchon M Grivaux B Asselain 2006 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index Lancet Oncol 7 829 836
5. C Bouffioux L Denis W Oosterlinck G Viggiano B Vergison F Keuppens M De Pauw R Sylvester B Cheuvart 1992 Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research and Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin J Urol 148 297 301
6. C Bouffioux KH Kurth A Bono W Oosterlinck CB Kruger M De Pauw R Sylvester 1995 Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of two European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group J Urol 153 Supplement 934 941
7. DR Cox 1972 Regression models in life-tables (with discussion) J Roy Stat Soc Ser B 34 187 220
8. Cramer H (1971) Mathematical methods of statistics. Princeton University Press, Princeton
9. L Duchateau P Janssen 2005 Understanding heterogeneity in mixed, generalized mixed and frailty models Am Stat 59 143 146
10. V Ducrocq G Casella 1996 A Bayesian analysis of mixed survival models Genet Sel Evol 28 509 529
11. Ducrocq V, Sölkner J (1994) The Survival Kit, a FORTRAN package for the analysis of survival data. In: 5th World congress on genetics applied to livestock production, vol 22. Department of Animal Poultry Science, University of Guelph, Guelph, Ontario, Canada, pp 51-52
12. Ducrocq V, Sölkner J (1998) The Survival Kit-V3.0, a package for large analysis of survival data. In: 6th World congress on genetics applied to livestock production, vol 27. Animal Genetics and Breeding Unit, University of New England, Armidale, Australia, pp 447-448
13. DV Glidden E Vittinghoff 2004 Modelling clustered survival data from multicentre clinical trials Stat Med 23 369 388
14. E Graf C Schmoor W Sauerbrei M Schumacher 1999 Assessment and comparison of prognostic classification schemes for survival data Stat Med 18 2529 2545
15. FE Harrell KL Lee DB Mark 1996 Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 361 387
16. Ibrahim JG, Chen MH, Sinha D (2001) Bayesian survival analysis. Springer-Verlag Inc, New-York
17. AC Justice KE Covinsky JA Berlin 1999 Assessing the generalisibility of prognostic information Ann Internal Med 130 515 524
18. Kendall M, Stuart A (1977) The advanced theory of statistics, vol 1: Distribution theory, 4th edn. London & High Wycombe, Charles Griffin & Company Limited
19. KH Kurth FH Schröder U Tunn R Ay R Pavone-Macaluso F Debruyne M De Pauw O Dalesio F Ten Kate 1984 Adjuvant treatment of superficial transitional cell bladder carcinoma: preliminary results of an European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone J Urol 132 258 262
20. Legrand C (2005) Assessing heterogeneity in multicenter clinical trials using the frailty model. PhD Thesis. Center for Statistics, Hasselt University
21. C Legrand V Ducrocq P Janssen R Sylvester L Duchateau 2005 A Bayesian approach to jointly estimate center and treatment by center heterogeneity in a proportional hazards model Stat Med 24 3789 3804
22. Y Matsuyama J Sakamoto Y Ohashi 1998 A Bayesian hierarchical survival model for the institutional effects in a multi-centre cancer clinical trial Stat Med 17 1893 1908
23. JA Nelder R Mead 1965 A Simplex method for function minimization Comput J 7 308 313
24. DW Newling MR Robinson PH Smith D Byar R Lockwood I Stevens M De Pauw R Sylvester 1995 Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer Results of a prospective randomized phase III study performed by the EORTC GU Group. EORTC Genitourinary Tract Cancer Cooperative Group Eur Urol 27 110 116
25. W Oosterlinck KH Kurth FH Schröder J Butlinck B Hammond R Sylvester 1993 A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage TaT1 papillary carcinoma of the bladder J Urol 149 749 752
26. H Putter M Fiocco RB Geskus 2007 Tutorial in biostatistics: competing risks and multi-state models Stat Med 26 2389 2430
27. S Ripatti K Larsen J Palmgren 2002 Maximum likelihood inference for multivariate frailty models using an automated Monte Carlo EM algorithm Lifetime Data Anal 8 349 360
28. P Royston MKB Parmar R Sylvester 2004 Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer Stat Med 23 907 926
29. M Schemper 2003 Predictive accuracy and explained variation Stat Med 22 2299 2308
30. M Schemper R Henderson 2000 Predictive accuracy and explained variation in Cox regression Biometrics 56 249 255
31. M Schemper J Stare 1996 Explained variation in survival analysis Stat Med 15 1999 2012
32. R Simon DG Altman 1994 Statistical aspects of prognostic factor studies in oncology Brit J Cancer 69 979 985
33. D Sinha JG Ibrahim MH Chen 2003 A Bayesian justification of Cox's partial likelihood Biometrika 90 629 641
34. A Smith AM Skene J Shaw J Naylor M Dransfield 1985 The implementation of the Bayesian paradigm Commun Stat Theory Meth 14 1079 1102
35. CT Smith PR Williamson AG Marson 2005 Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 24 9 1307 1319
36. P Solal-Celigny P Roy P Colombat 2004 Follicular lymphoma international prognostic index Blood 104 1258 1265
37. Spiegelhalter DJ, Abrams K, Myles JP (2004) Bayesian approaches to clinical trials and health care evaluation. Wiley, Chichester
38. RJ Sylvester APM Van der Meijden W Oosterlinck JA Witjes C Bouffioux L Denis DWW Newling K Kurth 2006 Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORT trials Eur Urol 49 466 477
39. L Tierney JB Kadane 1986 Accurate approximations for posterior moments and marginal densities J Am Stat Assoc 81 391 82 86
40. F Vaida R Xu 2000 Proportional hazards model with random effects Stat Med 19 3309 3324
41. HC Van Houwelingen 2000 Validation, calibration, revision and combination of prognostic survival models Stat Med 19 3401 3415
42. JA Witjes AP Van der Meijden RJ Sylvester FM Debruyne A Van Aubel WP Witjes 1998 Long term follow up of an EORTC randomized prospecive trial comparing intravesical bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer Urology 52 403 410
43. T Yamaguchi Y Ohashi 1999 Investigating centre effects in a multi-centre clinical trial of superficial bladder cancer Stat Med 18 1961 1971
44. T Yamaguchi Y Ohashi Y Matsuyama 2002 Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials Stat Methods Med Res 11 221 236